ARCHIMED /
Genetica
ARCHIMED acquires majority stake in Genetica
Source for the buyer and target: ARCHIMED
For the buyer and target.
“ARCHIMED acquired its majority stake in Genetica through the MED III fund, alongside Rise Investment, a Brazilian impact investment fund, as minority co-investor.”
Published 14 Oct 2026
Open the sourceWhat happened
ARCHIMED, the healthcare-focused investment firm, acquired a majority stake in Genetica through its MED III fund, alongside Brazilian impact fund Rise Investment as a minority co-investor. Genetica is ARCHIMED's first stand-alone investment in Brazil and the tenth investment of MED III. [01]
Founded in 2005 and headquartered in the Brazilian state of Santa Catarina, Genetica develops, manufactures and sells biological solutions for industrial wastewater treatment, biogas generation and bio-based crop protection, serving agribusiness, food and beverage, collagen and pharmaceutical customers. Ivan Sganderla and Anderson Bernardi are Genetica's co-founders, and Thibaut Mongon and Antoine Faguer are Partners at ARCHIMED. [01]
The source
Everything on this page comes from the source below, quoted word for word.
ARCHIMED acquires majority stake in Genetica
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
Deal Web
Every firm and person on this deal, and how they connect. Open any name to see their other deals.
Closed · ARCHIMED acquired a majority stake in Genetica (Closed, published 14 Oct 2026).
Published 14 Oct 2026- Published by ARCHIMED
By email · Weekly